Advocacy groups filed a lawsuit on behalf of 3 Medicaid recipients challenging Arkansas' Medicaid work requirements; CVS Health announced that its pharmacy benefit manager will target expensive drugs to be excluded from formularies if they are not cost effective; Senate leaders have received a letter from 120 consumer and patient associations on the impact Supreme Court nominee Brett Kavanaugh could have on health policy.
The Trump administration is facing another lawsuit over its decision to allow states to impose work requirements in Medicaid. Similar to an earlier lawsuit over Kentucky’s work requirements, advocacy groups filed a lawsuit on behalf of 3 Medicaid recipients in Arkansas, reported Reuters. The lawsuit claims the administration does not have the capability to approve work requirements under the federal Medicaid law. In June, a federal judge blocked Kentucky’s work requirements.
In a recent white paper, CVS Health announced that its pharmacy benefit manager will target expensive drugs to be excluded from formularies if they are not cost effective. According to The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, CVS Caremark will rely on data from the Institute for Clinical and Economic Review to determine cost effectiveness. CVS has already implemented efforts to curb costs, and the white paper identifies 3 additional strategies it will begin to employ.
Senate leaders have received a letter from 120 consumer and patient associations on the impact Supreme Court nominee Brett Kavanaugh could have on health policy. InsideHealth Policy reported that the Supreme Court might be hearing cases on the constitutionality of the Affordable Care Act, access to women’s healthcare services, state accountability for violating Medicaid requirements, and attempts to roll back Medicaid coverage. Kavanaugh could be a deciding vote on all of these health issues.
Health Equity and Access Weekly Roundup: December 9, 2023
December 9th 2023The Center on Health Equity and Access provides information on the latest news, research discoveries, and initiatives dedicated to addressing healthcare disparities and improving overall access to high-quality care.
Read More
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More